Collectively, both preclinical animal studies and human genetic surveys have provided compelling new insights into the pathogenesis of NAFLD/NASH and support the possibility that HSD17B13 may represent as a potential target for the treatment of NAFLD/NASH and chronic liver disease. The gene discussed is HSD17B13; the disease is metabolic dysfunction-associated steatohepatitis.